Advanced Cell Technology licenses somatic cell IP from TranXenoGen

By Lisa Kerner

Erie, Pa., April 3 - Advanced Cell Technology, Inc. said it has exclusively licensed a key intellectual property portfolio of issued and pending patents in regard to somatic cell reprogramming from TranXenoGen, Inc. of Shrewsbury, Mass.

The inventions described in the intellectual property portfolio cover techniques for the reprogramming of somatic cell nuclei (including the use of extracts), for the generation of cloned and/or transgenic animals and for the reprogramming of human cells, according to a news release.

"We are pleased to announce the exclusive licensing of this important intellectual property in the field of cellular reprogramming," chief executive officer William Caldwell said in the release.

"After reaching terms with TranXenoGen for an option on this portfolio last year, our team did considerable diligence on this intellectual property portfolio. This portfolio may have the earliest priority date in somatic cell nuclear transfer and is broad in scope of application."

Advanced Cell, based in Alameda, Calif., is a biotechnology company applying stem-cell technology in the emerging field of regenerative medicine.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.